Q32 Bio Inc. (QTTB): Operating Cash Flow
-$33.54M
Year ended 2025-12-31
-$19.83M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$33.54M | n/m | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | -$67.72M | n/m | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | -$18.68M | n/m | 2025-03-11, From 2023-01-01 |
| 2022-12-31 | -$113.66M | n/m | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | -$109.75M | n/m | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | -$94.33M | n/m | 2022-03-23, From 2020-01-01 |
| 2019-12-31 | -$91.36M | n/m | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | -$42.56M | n/m | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $6.48M | n/a | 2019-03-12, From 2017-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Q32 Bio Inc. (QTTB) | 2025-12-31 | -$33.54M | n/m |
| Agios Pharmaceuticals, Inc. (AGIO) | 2025-12-31 | -$372.98M | n/m |
| Nektar Therapeutics (NKTR) | 2025-12-31 | -$208.51M | n/m |
| Ocular Therapeutix, Inc (OCUL) | 2025-12-31 | -$204.88M | n/m |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $3.28M | n/m |
| Lexicon Pharmaceuticals, Inc. (LXRX) | 2025-12-31 | -$67.85M | n/m |
| Gossamer Bio, Inc. (GOSS) | 2025-12-31 | -$171.27M | n/m |
| Journey Medical Corp (DERM) | 2025-12-31 | -$12.44M | n/m |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | -$138.89M | n/m |
Compare QTTB, AGIO, NKTR, OCUL side by side · Screen every company in Pharmaceutical Preparations ↗